BRPI0714563B8 - métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato - Google Patents

métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato

Info

Publication number
BRPI0714563B8
BRPI0714563B8 BRPI0714563A BRPI0714563A BRPI0714563B8 BR PI0714563 B8 BRPI0714563 B8 BR PI0714563B8 BR PI0714563 A BRPI0714563 A BR PI0714563A BR PI0714563 A BRPI0714563 A BR PI0714563A BR PI0714563 B8 BRPI0714563 B8 BR PI0714563B8
Authority
BR
Brazil
Prior art keywords
cancer
drug
mammalian
screening
detecting
Prior art date
Application number
BRPI0714563A
Other languages
English (en)
Portuguese (pt)
Inventor
Bihain Bernard
Original Assignee
Transmedi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmedi Sa filed Critical Transmedi Sa
Publication of BRPI0714563A2 publication Critical patent/BRPI0714563A2/pt
Publication of BRPI0714563B1 publication Critical patent/BRPI0714563B1/pt
Publication of BRPI0714563B8 publication Critical patent/BRPI0714563B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Glass Compositions (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Peptides Or Proteins (AREA)
BRPI0714563A 2006-07-20 2007-07-20 métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato BRPI0714563B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291176A EP1887088A1 (en) 2006-07-20 2006-07-20 Transcription infidelity, detection and uses thereof
EP06291176.3 2006-07-20
PCT/EP2007/057541 WO2008009751A2 (en) 2006-07-20 2007-07-20 Transcription infidelity, detection and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0714563A2 BRPI0714563A2 (pt) 2015-04-14
BRPI0714563B1 BRPI0714563B1 (pt) 2019-07-02
BRPI0714563B8 true BRPI0714563B8 (pt) 2021-05-25

Family

ID=37496681

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714563A BRPI0714563B8 (pt) 2006-07-20 2007-07-20 métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato

Country Status (18)

Country Link
US (1) US8288091B2 (enExample)
EP (3) EP1887088A1 (enExample)
JP (1) JP5298013B2 (enExample)
KR (1) KR101502179B1 (enExample)
AT (1) ATE524565T1 (enExample)
AU (1) AU2007275068B2 (enExample)
BR (1) BRPI0714563B8 (enExample)
CA (1) CA2658305C (enExample)
CY (2) CY1112125T1 (enExample)
DK (2) DK2046986T3 (enExample)
ES (2) ES2373428T3 (enExample)
HU (1) HUE028135T2 (enExample)
IL (1) IL196600A0 (enExample)
PL (2) PL2046986T3 (enExample)
PT (2) PT2046986E (enExample)
SI (2) SI2468885T1 (enExample)
TR (1) TR201112295Y (enExample)
WO (1) WO2008009751A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2071334A1 (en) * 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2995688A1 (en) 2014-09-12 2016-03-16 Genclis Methods of prognosing and treating triple negative breast cancer
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
LT3430390T (lt) 2016-03-18 2022-11-25 Genclis Molekulinė alergijos kilmė
WO2018187216A1 (en) * 2017-04-03 2018-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression cassettes and methods for detecting transcription errors
EP3700856A4 (en) 2017-10-26 2021-12-15 Ultima Genomics, Inc. METHODS AND SYSTEMS FOR SEQUENCE CALL
CN113795887A (zh) 2019-03-10 2021-12-14 阿尔缇玛基因组学公司 用于序列判定的方法和系统
WO2021030271A2 (en) 2019-08-09 2021-02-18 Nutcracker Therapeutics, Inc. Methods and apparatuses for manufacturing for removing material from a therapeutic composition
KR102334576B1 (ko) * 2019-08-12 2021-12-07 한국생명공학연구원 융합 단백질 및 이를 포함하는 바이오 이미징용 조성물
EP4211268A4 (en) * 2020-09-10 2024-09-18 Ultima Genomics, Inc. SEQUENCE AND VARIANT CALLING METHODS AND SYSTEMS
WO2022108309A1 (ko) * 2020-11-18 2022-05-27 한양대학교 에리카산학협력단 인산화된 비멘틴의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
EP4162948A1 (en) 2021-10-05 2023-04-12 Genclis Transcription infidelity derived chimeric immunogens and uses thereof
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4979330A (en) 1989-10-10 1990-12-25 Rorant Julius W Suction insect trap device
US6120992A (en) 1993-11-04 2000-09-19 Valigene Corporation Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, and allele identification in a diseased human
WO2001040804A2 (en) * 1999-12-03 2001-06-07 Koninklijke Nederlandse Akademie Van Wetenschappen Clearance of aberrant protein in correlation with disease
US20020132259A1 (en) 2001-02-21 2002-09-19 Wagner Robert E. Mutation detection using MutS and RecA
WO2006053061A2 (en) * 2004-11-10 2006-05-18 Kansas State University Research Foundation Porcine reproductive and respiratory syndrome virus receptor components and uses thereof

Also Published As

Publication number Publication date
BRPI0714563A2 (pt) 2015-04-14
JP2009544284A (ja) 2009-12-17
HK1128937A1 (en) 2009-11-13
DK2046986T3 (da) 2012-01-02
PL2468885T3 (pl) 2016-04-29
KR101502179B1 (ko) 2015-03-12
CY1112125T1 (el) 2015-11-04
AU2007275068A1 (en) 2008-01-24
US8288091B2 (en) 2012-10-16
CA2658305C (en) 2017-07-18
TR201112295Y (tr) 2018-08-27
BRPI0714563B1 (pt) 2019-07-02
SI2468885T1 (sl) 2016-02-29
SI2046986T1 (sl) 2012-05-31
EP2468885A2 (en) 2012-06-27
WO2008009751A3 (en) 2008-07-31
DK2468885T3 (da) 2016-02-29
CY1116939T1 (el) 2017-04-05
US20090317386A1 (en) 2009-12-24
AU2007275068B2 (en) 2013-06-06
JP5298013B2 (ja) 2013-09-25
WO2008009751A2 (en) 2008-01-24
EP2468885B1 (en) 2015-08-19
ATE524565T1 (de) 2011-09-15
CA2658305A1 (en) 2008-01-24
HUE028135T2 (en) 2016-12-28
EP2046986A2 (en) 2009-04-15
IL196600A0 (en) 2009-11-18
ES2373428T3 (es) 2012-02-03
KR20090052861A (ko) 2009-05-26
EP2046986B1 (en) 2011-09-14
EP1887088A1 (en) 2008-02-13
ES2553435T3 (es) 2015-12-09
PL2046986T3 (pl) 2012-02-29
EP2468885A3 (en) 2012-08-29
PT2046986E (pt) 2011-12-29
PT2468885E (pt) 2015-11-26

Similar Documents

Publication Publication Date Title
BRPI0714563B8 (pt) métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato
Liu et al. The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
Hogg et al. Elevation of plasma tRNA fragments precedes seizures in human epilepsy
Yokoyama et al. DNA methylation alterations in Alzheimer’s disease
Mondello et al. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders
Carrard et al. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder
Song et al. Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients
Wang et al. Clinical significance of miR-433 in the diagnosis of Alzheimer's disease and its effect on Aβ-induced neurotoxicity by regulating JAK2
Di Narzo et al. A unique gene expression signature associated with serotonin 2C receptor RNA editing in the prefrontal cortex and altered in suicide
EP3190413B1 (en) Method for predicting depression treatment drug alternatives
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
EP3049532A2 (en) Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzheimer's disease (psad)
GB0524110D0 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
Elstner et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
Ruan et al. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: implication for the screening of cognitive frailty
WO2009026153A1 (en) Biomarkers for alzheimer's disease and methods using the same
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
Dada et al. Epigenetic studies in suicidal ideation and behavior
WO2007067476A3 (en) Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers
Nunes et al. Association of paraoxonase (PON) 1 activity, glutathione S-transferase GST T1/M1 and STin. 2 polymorphisms with comorbidity of tobacco use disorder and mood disorders
Kolarcik et al. Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease
EP2539709A4 (en) MORBUS ALZHEIMER SPECIFIC CHANGES OF PROTEIN KINASE C EPSILON (PKC EPSILON) PROTEIN MIRRORS
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2840 DE 10-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.